PSNL

Personalis, Inc. NGM · PSNL

$12.98 -0.46 (-3.42%)

Neutral · -0.43σ

+ Compare Open in Sniper

Mkt cap $1.4B

P/E —

Day $12.84 – $13.41

52wk $4.95 – $16.39

Avg vol 3.8M

Beta 2.24

Div yld —

Next earnings 2026-08-05

Quick read

At a glance

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.

PSNL last traded at $12.98, down 3.4% on the day; that's in the upper part of its 52-week range ($4.95–$16.39). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-08-05) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is sitting close to its normal range — no real dip to buy yet.

Long —

Setup score 16 / 100

Price is sitting close to its normal range — no real dip to buy yet.

· Aligned with breakout up (strong tailwind)

Technical read: above KC1 lower, -0.52 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — no real dip to buy yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 16 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

Setup score 6 / 100

Price is sitting close to its normal range — not meaningfully overheated yet.

· Counter-trend short in breakout up

Technical read: below KC1 upper, -0.52 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — not meaningfully overheated yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 6 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 6 pts

Cycle position 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Unknown Accounting: Weak

Fair-value range

$2.00 – $2.00

Accounting quality Weak

✓ More cash than debt
✓ Quick ratio 6.29 (antifragile)
✓ Current ratio 6.76 (antifragile)
✓ Debt/equity 0.28 (antifragile)

⚠ Negative retained earnings
⚠ Receivables growing faster than revenue
⚠ Inventory growing faster than revenue
⚠ Stock comp 14% of revenue (heavy dilution)

Key statistics

All statistics →

PSNL is a $1.4 billion company, it moves harder than the market (beta 2.2).

Market cap $1.4B

P/E ttm —

Beta 2.24

52w range $4.95 – $16.39

Avg volume 3.8M

Dividend yield —

Sector Healthcare

Next earnings 2026-08-05

52-week range · today's price

$4.95$16.39

More on PSNL

Options idea

See more →

CALL $12 2026-08-21

$1.30

PUT $15 2026-08-21

$1.70

Earnings

See more →

Last reported: 2026-05-07
EPS (act / est): -0.29 / -0.28
Surprise: -2.6%
Next report: 2026-08-05

About

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole e…